Infliximab vs adalimumab: mucosal healing at 12 weeks

What is known

• SIMCHA, a prospective open-label single-arm study of adalimumab in small-bowel CD, reported endoscopic healing in 47% and endoscopic response in 29% at 24 weeks. ¹
• The cited EXTEND randomized trial of adalimumab reported colonic mucosal healing of 27% at week 12 and 24% at week 52, no infliximab comparator arm. ¹
• Small-bowel mucosal healing is consistently lower than colonic healing across anti-TNF studies, so healing rates depend heavily on disease location. ¹

What is unknown / caveats

• No infliximab-vs-adalimumab head-to-head comparison in retrieval
• Adalimumab endpoint reported at 24 weeks, not the 12 weeks asked
• SIMCHA is single-arm, open-label, small-bowel-restricted, biologic-naive
• The retrieved corpus cannot establish any relative ranking of infliximab versus adalimumab for 12-week mucosal healing.

References

1. Wetwittayakhlang P, Verdon C, Starr M, Hahn GD, Golovics PA, Bessissow T, Afif W, Wild G, Bitton A, Lakatos PL. Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn's Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study. Turk J Gastroenterol. 2023. PMID: 37162506.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.